Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment : The State of the Science, Evaluation, Implementation, and Economics, Workshop Summary / Patlak, Margie (EDT)/ Nass, Sharyl J. (EDT)

ホーム
> 洋書
> 英文書
> Medical

Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment : The State of the Science, Evaluation, Implementation, and Economics, Workshop Summary

個数：

Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment : The State of the Science, Evaluation, Implementation, and Economics, Workshop Summary

Patlak, Margie (EDT)/ Nass, Sharyl J. (EDT)

ウェブストア価格 ¥8,600（本体¥7,819）
National Academies Press（2006/11発売）
外貨定価 US$ 41.00
ポイント 78pt

在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
通常6～9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
【重要ご説明事項】
1. 納期遅延や、ご入手不能となる場合がございます。
2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
3. 美品のご指定は承りかねます。

●3Dセキュア導入とクレジットカードによるお支払いについて

【入荷遅延について】
世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。

◆画像の表紙や帯等は実物とは異なる場合があります。

◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
また、洋書販売価格は、ご注文確定時点での日本円価格となります。
ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。

製本 Paperback:紙装版/ペーパーバック版／ページ数 112 p.
言語 ENG
商品コード 9780309101349
DDC分類 616

Full Description

Research has long sought to identify biomarkers that could detect cancer at an early stage, or predict the optimal cancer therapy for specific patients. Fueling interest in this research are recent technological advances in genomics, proteomics, and metabolomics that can enable researchers to capture the molecular fingerprints of specific cancers and fine-tune their classification according to the molecular defects they harbor. The discovery and development of new markers of cancer could potentially improve cancer screening, diagnosis, and treatment. Given the potential impact cancer biomarkers could have on the cost effectiveness of cancer detection and treatment, they could profoundly alter the economic burden of cancer as well. Despite the promise of cancer biomarkers, few biomarker-based cancer tests have entered the market, and the translation of research findings on cancer biomarkers into clinically useful tests seems to be lagging. This is perhaps not surprising given the technical, financial, regulatory, and social challenges linked to the discovery, development, validation, and incorporation of biomarker tests into clinical practice.
To explore those challenges and ways to overcome them, the National Cancer Policy Forum held the conference "Developing Biomarker-Based Tools for Cancer Screening, Diagnosis and Treatment: The State of the Science, Evaluation, Implementation, and Economics" in Washington, D.C., from March 20 to 22, 2006. At this conference, experts gave presentations in one of six sessions. In addition, seven small group discussions explored the policy implications surrounding biomarker development and adoption into clinical practice. Developing Biomarker-based Tools for Developing Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics-Workshop Summary presents the conference proceedings and will be used by an Institute of Medicine (IOM) committee to develop consensus-based recommendations for moving the field of cancer biomarkers forward.

1 Front Matter; 2 Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment; 3 Acronyms; 4 Glossary; 5 References; 6 Appendix A Workshop Agenda; 7 Appendix B Workshop Speakers, Moderators, Invited Discussants, and Participants